|
Aug 7
|
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information
|
|
Aug 5
|
VALNEVA Declaration of shares and voting rights: July 31, 2025
|
|
Jul 29
|
AGC Biologics’ Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva’s Tetravalent Shigella Vaccine Candidate
|
|
Jul 24
|
Valneva (VALN) Soars 17.4%: Is Further Upside Left in the Stock?
|
|
Jul 24
|
High Growth Tech Stocks In Europe With Promising Potential
|
|
Jun 26
|
Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
|
|
Jun 25
|
Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance
|
|
Jun 6
|
Valneva reports data from Phase II chikungunya vaccine trial in children
|
|
Jun 5
|
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®
|
|
Jun 5
|
[Valneva SE] Declaration of shares and voting rights - May 2025
|
|
Jun 4
|
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
|
|
Mar 10
|
High Growth Tech Stocks In Europe For March 2025
|
|
Feb 18
|
Valneva hits 2024 sales target but plans lower cash burn in 2025
|
|
Feb 18
|
Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook
|
|
Feb 17
|
Bavarian Nordic scoops FDA approval for chikungunya vaccine in adults and teens
|
|
Jan 3
|
VALNEVA Declaration of shares and voting rights: December 31, 2024
|